Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine effectiveness and tolerability in children with ADHD in Germany
NCT00191516Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Primary endpoint: Global Impression of Perceived Difficulties at 24 weeks. Started Oct 2004; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00191516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191516.